Northpond Ventures

Type

Venture Capital

Status

Active

Location

Bethesda, United States

Total investments

114

Average round size

41M

Portfolio companies

68

Rounds per year

19.00

Lead investments

26

Follow on index

0.40

Exits

3

Stages of investment
Venture
Areas of investment
BiotechnologyInformation TechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2018 was created Northpond Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Bethesda.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Northpond Ventures, startups are often financed by ARCH Venture Partners, Sands Capital Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are Sands Capital Ventures, Think.Health, Spring Mountain Capital. In the next rounds fund is usually obtained by National Cancer Institute SBIR Development Center, Think.Health, Spring Mountain Capital.

The real fund results show that this VC is 64 percentage points more often commits exit comparing to other companies. The fund is generally included in 13-24 deals every year. The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The current fund was established by Michael Rubin, Sharon Kedar. Besides them, we counted 3 critical employees of this fund in our database.

Among the various public portfolio startups of the fund, we may underline Ultivue, 908 Devices, Candel Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical, Software. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcareClimate tech
Stage focus
Series BSeries ASeed
Check size
Up to 10M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
114
Lead investments
26
Exits
3
Rounds per year
19.00
Follow on index
0.40
Investments by industry
  • Biotechnology (84)
  • Health Care (52)
  • Medical (30)
  • Health Diagnostics (29)
  • Life Science (26)
  • Show 39 more
Investments by region
  • United States (104)
  • United Kingdom (4)
  • Switzerland (1)
  • Australia (3)
  • Germany (2)
Peak activity year
2021

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Avg. valuation at time of investment
6M
Group Appearance index
0.84
Avg. company exit year
7

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Elephas Biosciences 30 Nov 2023 Health Care, Medical Device, Medical Late Stage Venture 55M United States, Wisconsin, Madison
EnPlusOne Biosciences 30 Sep 2022 Biotechnology, Therapeutics Seed 12M United States, Massachusetts, Watertown

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.